|
|
|
Ocular Therapeutix Inc (NASDAQ: OCUL) |
|
Ocular Therapeutix Inc
Officers & Directors
Merilee Raines Director Boston, Massachusetts Donald Notman Chief Financial Officer (Principal Financial and Accounting Officer) Pravin Dugel, M.D. Executive Chairman of the Board of Directors Richard L. Lindstrom, M.D. Director Antony Mattessich President, Chief Executive Officer and Director (Principal Executive Officer) Adrienne Graves, Ph.D. Director Leslie Williams Director Seung Suh Hong, Ph.D. Director Charles Warden Director ,
Ocular Therapeutix Inc currently has 325 employees.
News about Ocular Therapeutix Inc Key Personnel |
Ocular Therapeutix Accelerates Wet AMD Trials Amid Strategic Expansion and Legal Expertise EnhancementsIn the dynamic landscape of biopharmaceutical innovation, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has taken decisive steps towards solidifying its status as a pioneering leader in deve...
|
Ocular Therapeutix Inc, a leading biopharmaceutical company specializing in innovative eye therapies, recently announced significant additions to its clinical team. This strategic move aims to strengthen the company s medical expertise and propel its research and development efforts forward. Nadia K. Waheed, MD, MPH, has been appointed as the Chief Medical Officer, while Peter K. Kaiser, MD, will assume the role of Chief Development Officer. Additionally, Andrea Gibson, PhD, has been named Vice President of Medical Collaborations, and Namrata Saroj, OD, joins as the Development Strategy Consultant. This article delves into the implications of these appointments and analyzes their potential impact o...
|
In a recent announcement, Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on developing and commercializing innovative therapies for eye-related diseases, revealed that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu. These awards were approved by Ocular s Compensation Committee and were offered to Dr. Zhu as an incentive for joining the company.
Ocular Therapeutix is committed to improving people s vision and quality of life by creating treatments for conditions such as wet age-related macular degeneration (wet AMD) and diabetic retinopathy. The company aims to bring innovative therapies to ma...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
